Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,754 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: standard injections Clear all
Not listed Not applicable Interventional

Inpatient Self Monitoring and Administration Study (ISMAS)

NCT00506272
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Self blood glucose monitoring and insulin administration, Standard care
Procedure
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

iPad as a Distraction Tool During Facial Laceration Repair

NCT02217436
View directory record Official record
Conditions
Anxiety, Laceration Repair, Children
Interventions
iPad, Standard Care
Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
2 Years to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 4, 2026, 11:28 AM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Not yet recruiting Not applicable Interventional

Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy

NCT07553858
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis, Portal Shunt Systemic
Interventions
Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts, Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

NCT00920855
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bendamustine, bortezomib
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Encinitas, California • Roseville, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 4, 2026, 11:28 AM EDT
Terminated Phase 4 Interventional Results available

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

NCT05278858
View directory record Official record
Conditions
Alopecia Areata
Interventions
MedJet Device with intralesional triamcinolone
Combination Product
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 4, 2026, 11:28 AM EDT
Not listed Phase 2 Interventional

Efficacy of CTM for Tennis ELbow

NCT06171555
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis \(Tennis Elbow\), Lateral Elbow Tendinopathy
Interventions
CTM, Celestone
Device · Drug
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 4, 2026, 11:28 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effect of Ghrelin on Decision-Making

NCT03198143
View directory record Official record
Conditions
Healthy Volunteers, Obesity
Interventions
Ghrelin, Saline
Drug
Lead sponsor
Jenny Tong, MD, MPH
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 4, 2026, 11:28 AM EDT
Recruiting Phase 3 Interventional

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

NCT06945315
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
RALP (Robotic-assisted radical prostatectomy), SAFE (Saline assisted fascial engorgement)
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 4, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

NCT03151408
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pracinostat, Placebos, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 4, 2026, 11:28 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

NCT07472491
View directory record Official record
Conditions
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Recruiting Not applicable Interventional

J-Tip Use for Paracentesis in Adults With Ascites

NCT06996379
View directory record Official record
Conditions
Evaluate Patient Comfort Level During Paracentesis by Numbing Skin With a Needle-less Device, Instead of Using a Needle to Numb the Skin
Interventions
Experimental J-Tip Needle-Free Injection System, Control (Standard treatment)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT05616650
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
18F-DCFPyL, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Myocardial Perfusion Imaging Galmydar Rest/Stress

NCT05625490
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ga-68 Galmydar, 13N-ammonia
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

NCT03461718
View directory record Official record
Conditions
Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions
Ketamine, Midazolam injection, Fentanyl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 4, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 4, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional

Antibiotic Tumescent For Chronic Wounds

NCT06327113
View directory record Official record
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 4, 2026, 11:28 AM EDT
Terminated Phase 2 Interventional Results available

Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

NCT05378113
View directory record Official record
Conditions
Injection Site Irritation
Interventions
Ondansetron, Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 4, 2026, 11:28 AM EDT